| (1) |
Franklyn JA: The management of hyperthyroidism. N Engl J Med 1994; 330:
1731-8. |
| (2) |
Soloman B, Glinoer D, Lagasse R, Wartofsky L: Current trends in the management
of Craves' disease. J Clin Endocrinol Metab 1990; 70: 1518-24. |
| (3) |
Cooper DS: Antithyroid drugs for the treatment of hyperthyroidism caused
by Graves' disease. Endocrinol Metab Clin North Am 1998; 27: 225-47. |
| (4) |
Leech NJ, Dayan CM: Controversies in the management of Craves' disease.
Clin Endocrino] 1988; 49: 273-8O. |
| (5) |
Totter WR: The relative toxicity of antithyroid drugs. J New Drugs 1961;
2: 333-43. |
| (6) |
Ducomet B, Duprey J: Effects secondaires des antithyToidiens de synthese.
Ann Med Interne 1988; 134: 410-31. |
| (7) |
Meyer-Cessner M, Benker G, Olbricht TH, et al.: Nebenwirkungen der antithyreoidalen
therapie der hyperthryeose. Dtsch Med Wschr 1989; 114: 166-21. |
| (8) |
Hamberger Jl: Management of hyperthyroidism in children and adolescents.
J Clin Endocrinol Metab 1985; 60: 1019-24. |
| (9) |
Wiberg JJ, Nuttall FQ: Methimazole toxicity from high doses. Ann Intern
Med 1972; 77: 414-6. |
| (10) |
Benker G, Esser J, Kahaly C, Reinwein D: New therapeutic approaches in
thyroidal autoimmune diseases. Klin Wochensehr 1990; 68 (Suppl XXl): 44-54. |
| (11) |
Cooper DS, Coldminz D, Levin AA, et al.:Agranulocytosis associated with
antithyroid drugs. Ann Intern Med 1983; 98: 26-9. |
| (12) |
Vitug AC, Goldman JM: Hepatotoxicity form antithyroid drugs Horm Res 1985;
21: 229-34. |
| (13) |
Burrell CD, Fraser R, Doniach D: The low toxiciry of carbimazole Br Med
J 1956; 1: 1453-6. |
| (14) |
Werner MC, Romaldini JH, Bromberg N, Werner RS, Farah CS: Adverse effects
related to thionamide drugs and their dose regimen Am J Med Sci 1989; 296:
216-9. |
| (15) |
Wing ES Jr, Asper SP Jr: Observations on the use of propylthiouracil in
hyperhyroidism with especial reference to long term treatment. BulL Johns
Hopktns Hosp 1952; 90: 201-27. |
| (16) |
Suzuki S, Ichihawa K, Nagai M, et al.: Elevatior] ofserum creatine kinase
during treatment with antithyroid drugs in patients with hyperthyroidism
due lo Graves' disease. Arch Intern Med 1997; 157: 693-6. |
| (17) |
Hallman BL, Hurst JW: Loss of taste as toxic effect of merhimazole (tapazole)
therapy. J Am Med Assoc 1953; 152: 322. |
| (18) |
Genter MB, Deamer NJ, Biake BL, Wesley DS, Levi PE: Olfactory roxicity
of methimazole: dose-response and structure-activity studies and characterization
of flavin-containing monooxygenase activity in the Long-Evans rat olfacrory
mucosa. Toxicol Pathol 1995; 23: 477-86. |
| (19) |
Ahn YS, Yunis AA: Antithyroid therapy and leukocytes. In Drugs and Hematologic
Reactions, edited by Dimitrov NV, Nodine JH, pp. 249-69, New York, Grunne
and Stratton 1974. |
| (20) |
Meyer-Gessner M, Benker G, Lederbogen B, Olbricht T, Reinwein D: Antithyroid
drug induced agranulocytosis: clinical experience with ten patients treated
at one institution and review of the literature. J Endocrinol Invest 1994;
17: 29-36. |
| (21) |
Frenkel J, Tellez R, Reyes C, Gonzalez GM, Michaud P: Reacciones adversas
mayores a propiltiouracilo en 586 casos de hipertiroidismo Rev Med Chile
1993; 121: 1289-94. |
| (22) |
Tajiri J, Noguchi S, Murakami T, Murakami N: AntLthyroid druginduced agranulocytosis:
the usefulness of routine white blood cell count monitoring, Arch Intern
Med 1990; 150: 621-4. |
| (23) |
Retsagi G, Kelly JP, Kaufman DW: Risk of agranulocytosis and aplastic
anaemia in relarion to use of antithyroid drugs. Br Med J 1988; 297: 262-5. |
| (24) |
Mak NK, Lai WH, Liu WK, Leung KN, Fung MC: The effects of methimazole
on haematopoiesis in mice. Immunopharm Immunotox 1995; 17: 745-57. |
| (25) |
Salama A Mueller-Eckhardt C: Immune-mediated blood cell dyscrasias related
to drugs. Sem Hematol 1992; 29: 54-63. |
| (26) |
Walzer RA, Einbinder J: Immunoleukopenia as an aspect of hypersensitivity
to propylthiouraci[. J Am Med Assoc 1963; 184: 743-6. |
| (27) |
Toth EL, Mant MJ, Shivji S, Ginsberg J: Propylthiouracil-induced agranu[ocytosis:
an unusual presentation and a possible mechanism. Am J Med 1988; 85: 725-7. |
| (28) |
Weitzman SA, Slossel TP: Drug-induced immunologioal neutropenia. Lancet
1978; 1: I068-72. |
| (29) |
Berkman EM, Orlin JB, Wolfsdorf J: An antii-neutrophil antibody associated
with a propylchiouracil-induced lupus-like syndrome. Transfusion 1983; 23:
135-8. |
| (30) |
Wall JR, Fang SL, Kuroki T, [ngbar SH, Braverman LE: In vitro immunoreacrivity
to propylthiouracil, methimazole, carbimazole in patients with Graves' disease:
a possible cause of antithyroid druginduced agranulocytosis. J Clin Endocrinol
Metab 1984; 58: 868-72. |
| (31) |
Sato K, Miyakawa M. Han DC, et al.: Graves' disease with neutropenia and
marked splenomegaly: autoimmune neutropenia due ro propylthiouracil. J Endocrinol
Invest 1985; 8: 551-5. |
| (32) |
Fibbe WE, Claas FHJ, Van der Star-Dijkstra W, Schaafsma MR, Meyboom RHB,
Falkenburg JHF: Agranuiocytosis induced by propylthiouracil: evidence of
a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic
progeniror cells Br J Haematol 1986: 64; 363-73. |
| (33) |
Tamai H, Sudo T, Kimura A, el al.: Association between the DRB1*08032
histocompatibility antigen and methimazoleinduced agranulocytosis in Japanese
patients wlth Graves' disease Ann Intern Med 1996; 124: 490-4. |
| (34) |
Schut NH, Wiersinga WM, Van Oers MH: Methimazole-induced agranulocytosis
preceded by transient granulocytopenia. Neth J Med 1993; 43: 71-3. |
| (35) |
Shiran A, Shechner C, Dickstein C: Propylrhiouracil-induced agranulocytosis
in four patieuts previously treated with the drug. J Am Med Assoc 1991;
266: 3129-30. |
| (36) |
Tajiri J, Noguchi S, Murakami N: Usefulness of granulocyte count measurement
four hours after injection of granulocyte colony-stimulating factor for
detecting recovery from antithyroid drug.induced granulocytopenia. Thyroid
1997; 7: 575-8. |
| (37) |
Julia A, Olona M, Bueno J, et al.: Drug-induced agranulocytosis: prognostic
factors in a series of 168 episodes. Br J Haernatol 1991; 79: 366-71. |
| (38) |
Tajiri J, Noguchi S, Okamura S, et al.: Granulocyte colony-stimulating
factor treatment of antithyroid drug-induced granulocytopenia. Arch Intern
Med 1993; 153: 509-14. |
| (39) |
Drug-induced agranulocytosis. Drug Ther Bull 1997; 35: 49-52. |
| (40) |
Hamada N Itoh K, Mototani N , Nishikawa Y, Mimura T, Morii H: Effect of
corticosteroids in 10 cases of methimazole induced agranulocytosis. Endocrinol
Japon 1981; 28: 823-7. |
| (41) |
Tamai H, Mukura T. Matsubayashi S, et al.: Treatment of methimazole-induced
agranulocytosis using recombinant human granulocyte colony stimulating factor
(rhG-CSF) J Clin Endocrinol Metab 1993; 77: 1356-60. |
| (42) |
Chien MN, Wang CH. Tsan KW: Methimazole-induced agranulocytosis treated
with recombinant human granulocyte colony-stimulating factor (rhG-CSF):
a case report. Chung Hua i Hsueh Tsa Chih-Chin Med J 1995: 56: 351-5. |
| (43) |
O'Hare JA, Aaher T. Carbimazole induced agranulocytosis: rescue with human
recombinant granulocyte colony stimulating factor. Irish J Med Sci 1997:
166: 239-40. |
| (44) |
Westphal SA: Rccombinant hurman granulocyte colony-stimulating factor
in treatment of methimazole-induced agranulocytosis Endocrine Pract 1997:
3: 240-2. |
| (45) |
Fukata S, Murakami Y, Kuma K, Sakane S, Ohsawa N, Sugawara M: G-CSF Ievels
during spontaneous recovery from drug.induced agranulocytosis. Lancet 1993;
342: 1495. |
| (46) |
Fukata S, Kuma K, Sugawara M: Granulocyte colony-stimulating factor (G-CSF)
does not improve recevery from antithyroid druginduced agranulocytosis:
a prospective study. Thyroid 1999; 9: 29-31. |
| (47) |
Chen B. Lang R, Jutrin Y, Ravid M: Recurrent agranu[ocytosis induced by
two different antithyroid ageuts. Med J Aust 1983; 2: 38-9. |
| (48) |
Biswas N, Ahn YH, Goldman JM, Schwartz JM: Case-report: aplastic anemia
associated with antithyroid drugs. Am J Med Sci 1991; 301: 190-4. |
| (49) |
Herrera Pombo Jl, Cordido F, Vazquez C, Sanchea Fayos J: Aplastic anemia
caused by antithyroid drugs. Rev Clin Exp 1987; 181: 168. |
| (50) |
Kobayashi T, Ishiguro A, Andoh O, et al.: A case of drug-induced secondary
aplastic anemia [Japanese] Rinsho Ketsueki 1987; 28: 1587-92. |
| (51) |
Lopes Karpopvitch X, Ulloa Aguirre A, Von Eiff C, Hurtado Monroy A, Alania
A: Treatment of methimazole-induced severe aplastic anemia with recombinant
human granulocyte-monocyte colony stimulating factor and glucosteroids.
Acta Haematol 1992; 87: 148-50. |
| (52) |
Macia M Mendez M, Femandez M, Rivero A, Rios P: Severe pancitopenia associated
with antirhyroid drugs in a patien[t with Graves' disease and chronic renal
failure. Clin Nephrol 197?; 47: 69-70. |
| (53) |
Escobar-Morreale HF, Bravo P, Garcia-Robles R, Galcia-Larana J, de la
Calle H, Sancho JM: Merhtmazole-induced severe aplastic anemia: unsuccessful
treatment with recombinant human granulocyte-monocyte colony-stimulating
factor. Thyroid 1997; 7: 67-70. |
| (54) |
Mezquita P, Luna V, Munoz-Torres M, et al.: Methimazole-induced aplastic
anemia in third exposure: successful treatment with recombinant human granulocyte
colony-stimulating factor. Thyroid 1998; 8: 791-4. |
| (55) |
Moreb J, Shemesh O, Shilo S, Moanor C, Hershko C: Transient methimazole-induced
bone marrow aplasia: in vitro evidence for a humoral mechanism of bone marrow
suppression. Acta Haemat 1983; 69: 127-131. |
| (56) |
Shabtai R, Shapiro MS, Orenstein D, Taragan R, Shenkman L: The antithyroid
arthritis syndrome reviewed. Arth Rheum 1984; 27: 227-9. |
| (57) |
Bajaj S, Bell MJ, Shumak S, Briones-Urbina R: Antithyroid arthritis syndrome.
J Rheum 1988; 25: 1235-9. |
| (58) |
Tosun M, Guler M, Erem C, Uslu T, Miskioglu E: Intermittent polyarthritis
due to propylthiouracil. Clin Rheumatol 1995; 14: 574-5. |
| (59) |
Hietarinta M, Merilahti-Palo R: Methimazole-induced arthritis Scand J
Rheumatol 1989; 18: 61-2. |
| (60) |
Wing SS, Fantus IG: Adverse immunologic effects of antithyroid drugs.
Can Med Assoc J 1987; 136: 121-7. |
| (61) |
Prasad CVR, Bastacky S, Johnson JP: Propylthiouracil-induced diffuse prolifelative
lupus nephritis: review of immunological complications. J Am Soc Nephrol
1997; 8: 1205-10. |
| (62) |
Cassorla FG, Finegold DV, Parks JS, Tenore A, Thawerani H, Baker L: Vasculitis,
pulmonary cavitation, and anemia during antithyroid drug therapy Am J Dis
Child 1983; 137: I18-22. |
| (63) |
Miyazono K, Okasaki T, Uchida S, et al.: Propylthiouracil-induced diffuse
interstitial pneumonitis. Arch Intern Med 1984; 144: 1764-5. |
| (64) |
Amrein JA, Kenny FM, Ross D: Granulocytopenia, Iupus-like syndrome, and
other complications of propylthiouracil therapy. J Pediatr 1970; 76: 54-63. |
| (65) |
Horton RC, Sheppard MC, Emery P: Propylthiouracil-induced systemic lupus
erythematosus. Lancet 1989; 2: 568. |
| (66) |
Reidy TJ, Upshaw JD, Chesney T. Propylthtouracil-induced vasculitis: a
fatal case. Sourh Med J 1982; 75: 1297-8. |
| (67) |
Gunton JE, Steil J, Caterson RJ, McElduff A: Anti-thyroid drugs and antineutrophil
cytoplasmic antibody positive vasculitis. A case report and review of the
literature. J Clin Endocrinol Metab 1999; 84: 13-6. |
| (68) |
Dolman KM, Cans ROB, Vervaat ThJ, e[ al. Vasculitis and antineutrophil
cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet
1993; 342: 651-2. |
| (69) |
Ohtsuka M, Yamashita Y, Doi M, Hasegawa S: Propylthiouracilinduced alveoLar
haemorrhage associated with antineutrophil cytoplasmic antibody. Eur Resp
J 1997; 10: 1405-7. |
| (70) |
Miller RM, Savige J, Nassis L, Cominos BI: Antineulrophil cytoplasmic
antibody (ANCA)-positive cutaneous leucocytoclastic vasculitis associated
with antithyroid therapy in Graves' disease. Aust J Dermatol 1998; 39: 96-9. |
| (71) |
Fujieda M, Nagata M, Akioka Y, Hattori M, Kawaguchi H, Ito K: AntineutrophiI
cytoplasmic antibody-positive crescentic glomerulonephritis associated with
propylthiouracil therapyl. Acta Paediatrica Japonica 1998; 40: 286-9. |
| (72) |
D'Cruz D, Chesser AMS, Lightowler C, et al.: Antineutrophil cytoplasmic
antibody-positive crescentic glomerulonephritis associaced with anti-thyroid
drug treatment. Br J Rheum 1995; 34: 1090-1. |
| (73) |
Lee H, Hirouchi M, Hosokawa M, Sayo H, Kohno M,Kariya K: Inactivation
of peroxidase of rat bone marrow by repeared administration of propylthiouracil
is accompanied by a change in the heme structure. Biochem Pharmacol 1988;
37: 2151-3. |
| (74) |
Hosoi K, Makino S, Yamano Y, et al.: Cryofibrinogenemia with polyarthralgia.
Raynaud's phenomenon and oral ulcer in a patient with Graves' disease treated
with methimazole. Int Med 1997; 36: 439-42. |
| (75) |
Keren G, Boichis H, Lehr V: Erythema nodosum related to propylthiouracil
treatment for thyrotoxicosis. Isr J Med Sci 1985; 21: 62-3. |
| (76) |
Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA: Fifty years of
experience with propylthiouraci]-associa[ed hepatoroxicity: what have we
learned? J Clin Endocrinol Metab 1997; 82: 1727-33. |
| (77) |
Ozenirler S, Tuncer C, Boztepe G, et al.: Propylthiouracil-induced hepatic
damage. Ann Pharmacother 1996; 30: 960-3. |
| (78) |
Deidiker R, deMello DE: Propylthiouracil-induced fulminant hepatitis:
case report and review of the literature. Pediatr Parh Lab Med 1996; 16:
845-52. |
| (79) |
Hardee JT, Barnett AL, Thannoun A, Eghtesad B, Wheeler D, Jamal MW: Propylthiouracil-induced
hepatotoxicity West J Med 1996; 165: 144-7. |
| (80) |
Lock DR, Sthoeger ZM: Severe hepatotoxicity on beginning propylthioulacil
therapy. J Clin Castroenterol 1997; 24: 267-9. |
| (81) |
Ichiki Y, Akaboshi M, Yamashita N, et al.: Propylthiouracilinduced severe
hepatitis: a case report and review of the lilerature J Castroenterol 1998;
33: 747-50. |
| (82) |
Waseem M, Seshadri KC, Kabadi UM: Successful outcome with methimazole
and lithium combination therapy for propylthiouracil-induced hepatotoxicity.
Endocrine Pract 1998; 4: 197-200. |
| (83) |
Khovidhunkit W, Farese RV: Resolution of propylthiouracilinduced hepatic
failure after treatment of thyrotoxicosis. West J Med 1997; 167: 353-6. |
| (84) |
Morris CV, Coldstein RM, Cofer JB, Solomon H, Klintmalm GB: An unusual
presentation of fulminant hepatic failure secondary to propylthiouracil
therapy Clin Transplant 1989; 311. |
| (85) |
Limaye A, Ruffolo PR: Propylthiouracil-induced fatal hepatic necrosis.
Am J Gastroenterol 1987; 82: 152-4. |
| (86) |
Podevin P, Biour M: Drug-induced allergic hepatitis. Clin Rev Allergy
Immunol 1995; 13: 223-44. |
| (87) |
Van Pelt F, Strau P, Manns MP: Molecular basis of drug-induced immunological
liver injury. Sem Liver Dis 1995; 15: 283-300. |
| (88) |
Weiss M, Hassin D, Bank H: Propylthiouracil-induced hepatic damage. Arch
Inrern Med 1980; 140: 1184-5. |
| (89) |
Parker WA: Propylthiouracil-induced hepatotoxicity. Clin Pharm 1982; 1:
471-4. |
| (90) |
Larrey D, Pageaux GP: Cenetic predisposition to drug-induced hepatotoxicity.
J Hepatol 1997; 2: 12-21. |
| (91) |
Colwell SJ: Propylthiouracil-induced agranulocytosis, toxic hepatitis,
and death. J Am Med Assoc 1952; 148: 639-41. |
| (92) |
Pacini F, Sridama V, Refetoff S: Multiple complications of propylthiouracil
treatment: granulocytopenia, eosinophilia, skin reaction, and hepatitis
with lymphocyte sensitization j Endocrinol Invest 1982; 5: 403-7. |
| (93) |
Seidman DS Livni E Ilie B, Blum I: Propylthiouracil-induced cholestatic
jaundice. Clin Toxicol 1986; 24: 353-60. |
| (94) |
Hanson JS: Propylthiouracil and hepatitis. Arch Intern Med 1984; 144:
994-6. |
| (95) |
Levy M: Propylthiouracil hepatototicity: a review and case presentation.
Clin Pediatr 1993; 32: 25-9. |
| (96) |
Kirsh BM, Lam N, Layden TJ, Wiley TE: Diagnosis and management of fulminant
hepatic failure. Compr Ther 1995; 21: 166-71. |
| (97) |
Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ: Hepatic injury during
propylthiouracil therapy in patients with hyperthyroidism, Ann Intem Med
1993; 118: 424-8. |
| (98) |
Huang MJ, Li KL, Wei JS, Wu SS, Fan KD, Liaw YF; Sequential liver and
bone biochemical changes in hyperthyroidism: prospective controlled follow-up
study. Am J Gastroenterol 1994; 89: 1071-6. |
| (99) |
Epeirier J-M, Pageaux G-P, Coste V, Et al : Fulminant hepatitis after
carbimazole and propranolol administration. Eur J Castroenterol Hepatol
1996; 8: 287-8. |
| (100) |
Schwab GP, Wetscher GJ, Vogl W, Redmond E: Methimazoleinduced cholestatic
liver injury, mimicking sclerosing cholangitis. Langenbecks Arch Chir 1996;
381: 225-7. |
| (101) |
Becker CE, Gorden P, Robbins J; Hepatitis from methimazole during adrenal
steroid therapy for malignant exophthalmos. J Am Med Assoc 1968; 206: 1787-9. |
| (102) |
Fisher MG, Nayer HR, Miller A: Methimazole-induced iaundice. J Am Med
Assoc 1973; 223: 1028-9. |
| (103) |
King PD, Blitzer BL; Drug-induced cholestasis: pathogenesis and clinical
features, Semin Liver Dis 1990; 10: 316-21. |
| (104) |
Blom H, Stolk J, Schreuder HB, von Blomberg-van der Flier M: A case of
carbimazole-induced intrahepatic cholestasis, Arch Intern Med 1985; 145:
1513-5. |
| (105) |
Arab DM, Malatjalian DA, Rittmaster RS; Severe cholestatic jaundice in
uncomplicated hyperthyroidism treared with methimazole J Clin Endocrinol
Metab 1995; 80: 1083-5. |
| (106) |
Hofbauer LC, Heufelder AE: Coagulation disorders in thyroid disease. Eur
J Endocrinol 1997; 136: 1-7. |
| (107) |
Goldstein JD; Hypoprothrombinemia in hyperthyroidism. Med Clin North Am
1951; 35: 615-9. |
| (108) |
Craddock CG, Shotton D, Crockett CL, Leavell BS; Severe hypoprothrombinemia
following propylthiouracil treatment of thyrotoxicosis, N Engl J Med 195l;
244: 549-51. |
| (109) |
Mirrer GP; Hypoprothrombinemia following the use of propylthiouracil:
case report. Ann Intern Med 1955; 43: I124-7. |
| (110) |
D'Angelo G, LeGresley L: Severe hypoprothrombinaemia after propylthiouracil
therapy. Canadian Med Assoc J 1959; 81: 479-1. |
| (111) |
Kolars CP, Conyea Lh!1: Deficiency of prothrombin and procon-Yertin after
therapy with propvlthiouracil, J Am Med Assoc 1959; 171: 2315-9. |
| (112) |
Naeye RL, Terrien CM; Hemorrhagic state after therapy with propylthiouracil.
Am J Clin Pathol 1960; 34: 254-7. |
| (113) |
Gilbert DK: Hypoprothrombinemia as a complication of propylthiouracil.
J Am Med Assoc 1964; 189: 855. |
| (114) |
Cotta AW, Sullivan CA, Seaman J, Jean-Gilles B; Prolonged intraoperative
bleeding caused by Propylthiouracil-induced hypoprothrombinemia. Anesthesiology
1972; 37: 562-3. |
| (115) |
Ikeda S, Schweiss JF: Excessive blood loss during operation in the patient
treated with propylthiouracil. Anaesth Soc J 1982; 29: 476-80. |
| (116) |
Physician's Desk Reference. Montvale, NJ, Medical EconomicsCo., Inc. 1999. |
| (117) |
Lipsky JJ, Gallego MO: Mechanism of thioamide antithyroid drug associated
hypoprothrombinemia. Drug Metab Drug Interact 1988; 6: 317-26. |
| (118) |
Self TD, Weisburst M, Wooten E, Straughn A, Oliver J ; Warfarininduced
hypoprothrombinemia. J Am Med Assoc 1975; 231: 1165-6. |
| (119) |
Hiata Y, Tominaga M, Ito JI, Noguchi A: Spontaneous hypogIycemia with
insulin autoimmuniyy in Graves' disease. Ann Inern Med 1974; 81: 215-8. |
| (120) |
Hirata Y: Methimazole and insulin autoimmune syndrome with hypoglycaemia.
Lancet 1983; 2: 1037-8. |
| (121) |
Takei M: Insulin autoantibodies produced by methimazole treatment in the
patients with Graves' disease [japanese] J Tokyo Women's Med Coll 1980;
5O: 54-68. |
| (122) |
Hong-Da L, Hsin-Dean C, Pi-Yung C, Ching-Yuang L, King-Nien C: Insulin
autoimmune syndrome in methimazole or carbimazole treated Chinese patients
of Graves' disease. Chin Med J 1988; 42: 163-8. |
| (123) |
Nuovo JA, Baker JR, Wartofsky L, Lukes YG, Burman KD: Autoantibodies to
insulin are present in sera of patients with autoimmune thyroid disease.
Diabetes 1988; 37: 317-20. |
| (124) |
Sanke T, Kondo M, Moriyama Y, Nanjo K, Iwo K, Miyamura K: Clucagon binding
autoantibodies in a patient with hyperthyroidism treated with methimazole.
J Clin Endocrinol Metab 1983; 57: 1140-4. |
| (125) |
Masuda A, Tsushima T, Shizume K, et al.: Insulin autoimmune syndrome with
insulin-resistant diabetes at the incipient stage prior to hypoglycemic
attacks. J Endocrinol Invest 1986; 9: 507-12. |
| (126) |
Lee YJ, Shin SJ, Tomg JK, Liu WJ, Tsai JH: Insulin autoimmune syndrome
in a methimazole-treated Graves' patient with polyclonal anti-insulin autoantibodies:
report of a case. J Formosan Med Assoc 1987; 86: 164-70. |
| (127) |
Lu CC, Lee JK, Lam HC, Yang CY, Han TM: Insulin autoimmune syndrome in
a patient with methimazole and carbimazole-treated graves' disease: a case
report. Chin Med J 1994; 54: 352-8. |
| (128) |
Hakmata M, Itoh M, Sudo Y, Miyata N: Insulin autoimmune syndrome after
the third therapy with methimazole. Int Med 1995; 34: 410-2. |
| (129) |
Uchigata Y, Kuwata S, Tsushima T et al.; Patients with Graves' disease
who developed Insulin autoimmune syndrome (Hirata disease) possess HLA-Bw62/Cw4/DR4
carrying RBI*0406. J Clin Endocrinol Metab 1993; 77: 249-54. |
| (130) |
Moehlig RC: Parotid gland swelling due to methimazole. J Am Med Assoc
1969; 209: 1224. |